Purpose: Incidence of status epilepticus (SE) ranges from 6.8 to 41.0 per 100,000 population. Although SE is associated with significant morbidity and mortality, the temporal relationship between SE, epilepsy, and mortality is less clear. The risk of all-cause mortality following SE with and without prior epilepsy was investigated. Method: This study identified hospitalizations and emergency department visits for persons with SE and persons with epilepsy between 2000 and 2013. Excluded were those with epilepsy subsequent to SE, epilepsia partialis continua, less than 90 days follow-up, and less than 2 years of data prior to first diagnosis. The cohort was grouped into: 1) SE only, 2) post-epilepsy SE (PES), and 3) epilepsy only. The risk of mortality was estimated using Cox proportional hazard models adjusting for potential confounders. Results: The cohort (N = 82,331) consisted of 1296 SE only cases (1.6%); 2136 PES cases (2.6%); and 78,899 epilepsy only controls (95.8%) with 24.9%, 29.2% and 20.0% mortality, respectively. Compared with controls, the hazard of mortality was increased for those with SE only (hazard ratio [HR] = 1.61, 95% CI = 1.41-1.82) and PES (HR = 1.16, 95% CI = 1.07-1.25) after adjustment for demographic and clinical factors. Prior stroke, central nervous system infection, and brain tumor increased the mortality hazard. Conclusion: There is a statistically significant increased risk of all-cause mortality with SE. The risk is stronger in those with no prior epilepsy. Specific etiologies increase mortality risk in those with SE warranting further investigation of the complex associations between these etiologies and SE.
Introduction
According to the 2012 Neurocritical Care Society guidelines [1] , status epilepticus (SE) is a neurologic emergency associated with significant morbidity and mortality that is defined as either: 1) repeated seizures with failure to regain baseline mental status between convulsions, or 2) continuous seizures lasting 5 min (changed from the previous definition of a seizure length of 30 min) [2] . The annual incidence of SE is estimated to range from 6.8 to 41 cases per 100,000 population [3, 4] . Differences in SE incidence have been observed by age, race/ethnicity, and sex probably due to differing causes of SE, such as preexisting epilepsy, stroke, acute traumatic brain injury (TBI), central nervous system (CNS) infection, and alcohol abuse, etc. [3] [4] [5] . Previous studies have reported a higher incidence of SE among infants aged 1 year and older adults aged >60 years [6, 7] , persons of nonwhite racial/ethnic groups [3] , and males [8] . Nationally, the prevalence of SE is approximately 125,000-200,000 cases per year [9] . SE accounts for up to 10% of epilepsy-related deaths [10] . Mortality from SE ranges from 3% to 40% and is dependent on several factors including etiology and duration of SE [11] . The risk of mortality has been found to be six times higher among persons with epilepsy (PWE) with SE as the first seizure event compared with a reference population of PWE without history of SE (relative risk [RR] = 6.3, 95% CI: 1.5, 26.0) [12] . Several studies have examined the association of risk of mortality in SE with or without epilepsy [12] [13] [14] [15] [16] . However, there is limited information on the risk of mortality from any cause after SE as a function of onset of epilepsy, especially from population-based studies in a diverse population. The aim of the current study is to characterize persons with SE and PWE by survival status. Based on the strong association between mortality and etiology of acute SE [17] and the temporal occurrence of SE with or without prior epilepsy, we hypothesized that persons with SE, regardless of onset of epilepsy, will have higher mortality than PWE without SE.
Methods

Data sources
South Carolina (SC) non-federal hospital discharge and emergency department (ED) visit data, reported via the uniform billing system (UB-04) and provided by the SC Revenue and Fiscal Affairs Office, Health and Demographics Section, were analyzed for this statewide retrospective cohort study. Data elements available include International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes for primary diagnosis and up to fourteen secondary diagnoses per encounter [18] . The outcome of interest, all-cause mortality, was obtained from the SC Death Dataset and defined by underlying cause of death codes classified according to the International Classification of Diseases, 10th revision (ICD-10). This study received approval from the Medical University of South Carolina Institutional Review Board.
Study population/subjects
All individuals hospitalized or treated in the ED or SC hospitalbased outpatient departments (OPD) from January 1, 2000 to December 31, 2013 with ICD-9-CM diagnosis codes for SE, epilepsy, or 'Seizure Not Otherwise Specified (NOS)', as defined below, were selected. The occurrence of SE was determined based on at least one diagnosis code for grand mal SE (ICD-9-CM: 345.3); individuals with SE were further characterized by the presence or absence of a prior epilepsy diagnosis resulting in two SE groups: 1) SE only (no epilepsy prior to or following SE until event/censoring); or 2) post-epilepsy SE (PES) (epilepsy with later diagnosis of SE). For the purposes of this analysis, a diagnosis of epilepsy was ascertained according to the following set of criteria based on a published algorithm [19] : 1) at least one diagnosis for epilepsy (ICD-9-CM: 345.0-345.1, 345.4-345.6, or 345.8-345.9); 2) >1 unprovoked Seizure NOS (ICD-9-CM: 780.39) within 1 year; or 3) a single diagnosis of 'Seizure NOS' plus an indicator of epilepsy (i.e., vagal nerve stimulation, epilepsy surgery, electroencephalography (EEG) affirmation, or ketogenic diet in persons aged <19 years). The control-cohort included diagnosis with epilepsy without SE during the study period (i.e. prior to or following epilepsy until event/ censoring).
The presence of epilepsy-related comorbid conditions at any point in time during the study period was determined by ICD-9-CM codes assigned to diagnoses documented by clinicians at discharge and enumerated. The number of epilepsy-related comorbidities per person was categorized as: 0, 1-2, 3-5, 6-7, and 8 or more [20] . Supplementary Table S1 (in the online version, at doi:http://dx.doi. org/10.1016/j.seizure.2016.08.009) shows ICD-9-CM codes for the outcome, exposure, etiologies of SE, and comorbid conditions of epilepsy classified as somatic, psychiatric, or neurodevelopmental. Etiologies of SE are the acute, remote symptomatic and idiopathic causes of SE (e.g. CNS infection, hypoxia, low anticonvulsant drugs, etc.) [9] ; etiologies of interest to the current study included the following conditions: TBI, stroke, CNS infection and brain tumor. Race/ethnicity was characterized as: white, black, Hispanic, or other, which included all other races/ethnicities. Age was categorized by the following age groups: <1, 1-5, 6-18, 19-34, 35-64, and 65 years. In addition, the average number of hospitalizations/ED visits per year were reported and categorized as: 0-1, 2-4, and 5 or more.
Exclusion criteria
Out of state residents were excluded as were individuals with diagnosis of epilepsia partialis continua (ICD-9-CM: 345.7x) due to controversy regarding its classification as SE or epilepsy. Also excluded were individuals with a diagnosis of epilepsy subsequent to SE and those with missing or invalid dates of death. In order to reliably assess the absence of a prior diagnosis of epilepsy or SE, a two year intervening period was incorporated for individuals over two years old; those with fewer than two years of data before the first diagnosis of either epilepsy or SE were excluded. Children aged two and under (perforce having less than two years of data) were excluded only if their first diagnosis was in 2000 or 2001. Those diagnosed with SE or epilepsy with fewer than 90 days of follow-up to the censoring date of December 31, 2013 (i.e. October 2, 2013) who did not experience the event of interest, mortality, were excluded to ensure at least 90 days of follow-up time. Also excluded were those with implausibly high numbers of average hospitalization/emergency department visits (>365 visits per year). Exclusion criteria are displayed in Fig. 1 .
Statistical analysis
Significant differences in proportions were compared by mortality status using the difference of two independent proportions drawn from the same population. In addition, differences in age, the number of comorbid conditions and average hospitalizations/ED visits per year were assessed by mortality status using the Wilcoxon rank-sum test. Cox proportional hazards models were used to estimate unadjusted and adjusted hazard ratios (HRs) and 95% CIs of death as a function of time. Theendpoint was date of death or the censoring date of December 31, 2013. Potential confounders simultaneously evaluated were specific etiologies of SE, demographic (sex, race/ethnicity, age, and insurance status) and clinical characteristics (average number of hospitalization or ED visits per year, number of epilepsyrelated comorbidities [see Supplemental Table S1 in the online version, at doi:http://dx.doi.org/10.1016/j.seizure.2016.08.009]). The model assumptions of proportionality were evaluated with log-log plots; tests of nonzero slope in a generalized linear regression of scaled Schoenfeld residuals for each covariate vs. time; and tests of the significance of time-dependent covariates to the model [21] . Survival time was defined as the time from first diagnosis of SE (case cohorts) or epilepsy (control cohort) to death or censoring. Log-rank tests were used to evaluate differences in median survival time. All analyses were conducted using SAS software, version 9.3 (SAS Institute, Cary, NC) and figures were created by replicating the analysis using STATA software, release 13.1 (StataCorp LP, College Station, TX) due to the high quality graphics of STATA.
Results
A total of 82,331 PWE or persons with SE were included in the study, of whom 1.6% (n = 1296) had SE only (case-cohort 1), 2.6% (n = 2,136) had PES (case-cohort 2), and 95.8% (n = 78,899) had epilepsy only without a diagnosis of SE through the end of followup (control cohort) (data not shown). Characteristics of the case and control cohorts are displayed in Table 1 by mortality status; most demographic and clinical characteristics were significantly different by mortality status (p < 0.05).
Mortality and potential etiologies of SE
Between January 2000 and December 2013, a total of 16,755 deaths were observed; this included 24.9% of SE only cases (n = 323), 29.2% of PES cases (n = 624), and 20.0% of epilepsy only controls (n = 15,808) ( Table 1 ). The median time to death for the three groups was also calculated (data not shown). SE only cases had the shortest survival. Survival time differed significantly between the case groups as well as for both case groups compared to controls (p < 0.001). Six hundred eighty-six deaths occurred within 30 days, 48 of which occurred within 7 days (Fig. 2) .
Mortality by specific etiologies of SE identified from the literature was also examined by cohort status (case or control) as the proportion of total deaths for each group. Mortality for those with prior TBI was similar for persons with PES and epilepsy only (5.9% and 6.3%, respectively), but was lower for persons with SE only (1.5%). Among those with prior stroke, the mortality ranged from 23.5% for persons with SE only to 26.8% for persons with PES and 27.3% for epilepsy only controls. Mortality also differed slightly for those with prior CNS infection (1.9%, 2.4%, and 1.1% among persons with SE only, PES, and epilepsy only, respectively) and prior brain tumor (4.0%, 5.3%, and 3.7%, respectively) (Fig. 3) .
Hazard of mortality by case group and etiology
Persons with SE only (HR = 1.61, 95% CI: 1.42-1.83) and PES (HR = 1.15, 95% CI: 1.06-1.25) had significantly elevated risk of mortality after adjusting for covariables ( Table 2 ). The risk of mortality was also significantly elevated for those with specific etiological factors of SE, such as prior stroke (HR = 1.13, 95% CI: 1.09-1.17), prior CNS infection (HR = 1.25, 95% CI: 1.09-1.42) and prior brain tumor (HR = 1.82, 95% CI: 1.68-1.97) compared to those without a history of those etiological factors. Risk of mortality significantly increased after age 35 with risk increasing with advancing age. The risk of mortality was significantly increased for those with 1 or more comorbid conditions (with the exception of those with 8 or more comorbid conditions), but did not show a dose response. Having an average of 2 hospitalizations/ED visits per year increased the risk of mortality with mortality risk substantially increased for those with 5 hospitalizations/ED visits per year.
The cumulative hazard of mortality among individuals diagnosed with SE or epilepsy with specific underlying etiological factors for SE after adjustment for covariables is shown in Fig. 3 . The highest cumulative risk of mortality was observed among those with prior brain tumor followed by prior CNS infection and prior stroke.
Discussion
This study explored the risk of all-cause mortality among persons with SE, with or without prior diagnosis of epilepsy, relative to epilepsy only without any documented diagnosis of SE. After adjusting for covariables, the results show a strong association between risk of death and SE without prior epilepsy diagnosis compared with epilepsy only and a statistically significant but weak association between mortality and SE with clinically established prior epilepsy, confirming our hypothesis that SE would increase the risk of mortality. Further, our finding is consistent with a prior study showing overall better survival when SE occurs with established epilepsy compared with SE and no prior epilepsy [17] . PWE undergo regular clinical observation that may afford the early opportunity to detect clinical conditions, such as stroke and brain tumors, which may predispose to SE [22] . It is also possible that, through epilepsy education and communication with epilepsy health care providers, PWE may have heightened awareness and subsequent avoidance of external triggers of SE, such as substance abuse [23] .
Among the important results of this study is the comparable risk of mortality in the first three years of observation between persons with PES and PWE without SE. While the SE only cohort appears to have higher risk of both short-and long term mortality than those with PES, after about 8 years the survival becomes comparable. We suspect that PWE who develop subsequent SE may receive clinical interventions more rapidly because of the preexisting epilepsy. Despite the limited clinical information of our data, one potential conclusion is justification of the aggressive (and costly) treatment of SE in those with and without prior diagnosis with epilepsy, including mechanical ventilation and medication-induced coma (adherent to best practices) [1, 24, 25] , as the SE only group appears to have higher risk of short term mortality. The intriguing finding that mortality risk appeared relatively stable regardless of number of comorbidities may further support the conclusion that the underlying etiology of SE is a critical predictor of mortality. Those with prior stroke, brain tumor, or CNS infection had higher mortality rates in people with SE, supporting previous reports of increased mortality with these etiologies for SE [17] . Higher mortality was observed among persons over 18 years of age (increasing mortality with increasing age), those of male gender, and those with at least 1 epilepsy-related comorbidity. Persons with 2 or more average hospitalizations/ED visits per year and with Medicare, Medicaid or commercial insurance (compared to the uninsured) also experienced increased mortality.
Logroscino et al. observed increased long-term mortality for PWE with SE (n = 5) as the first seizure event compared with PWE without SE (n = 118) as the first seizure event (RR = 6.3, 95% CI: 1.5, 26.0) after adjustment for age and sex, although this study involved a small sample size [12] . There are additional reports from Brazil and Taiwan highlighting increased mortality risk in those with SE vs. a single seizure as the initial presentation of epilepsy in adults over 60 years of age (OR = 12.8, 95% CI: 2.3, 72) [26] . Case-fatality rates from SE, reported by several studies, have shown short-term mortality (defined as 30 days) ranging from 7.6% to 22% and long-term mortality (characterized by >30 days to 10 years) nearly doubled to 43% [4, 9, [27] [28] [29] [30] [31] . Ristic et al. assessed long-term survival in Serbian patients with SE and reported a total of 46 deaths (22%) among 207 patients at the end of the study in 2006, with length of follow-up depending on enrollment, which varied from 1989 to 1997 [32] . Our findings expand these studies by providing 1) a population-based estimate of mortality after SE, with the identification of specific risk factors and 2) a comparison to a cohort with epilepsy without diagnosis of SE.
There are a number of important possible clinical interpretations of our study. These data suggest that among persons with SE, etiology is a key factor not only for acute survival, but also for mortality. Although elevated mortality risk was observed for persons with SE with or without prior diagnosis of epilepsy, the risk of mortality was higher among those with SE only. This may be due in part to the underlying etiology of SE or may be related to residual confounding in the adjusted models. Given the high mortality associated with SE (up to 40%) [11] and because it accounts for nearly 10% of all epilepsy-related deaths [10] , SE represents a significant public health concern. Better understanding the role of underlying etiologies of SE and other potential risk factors for mortality, such as socioeconomic status (SES) factors, and common comorbidities of epilepsy, may serve as important clues in reducing mortality in this population.
Further analysis was done by age group as possible etiologies of SE and epilepsy are likely to differ by age group. Supplementary Tables S2 and S3 (in the online version, at doi:http://dx.doi.org/ 10.1016/j.seizure.2016.08.009) describe the cohort by age group and give the HR by age group, respectively. In Supplementary  Table S2 , at younger ages, the SE only group and the epilepsy only group had comparable proportions of deaths; both were lower than the PES group. In Supplementary Table S3, in the youngest age group, the cases and control groups did not differ; significant predictors of mortality were having a prior stroke (HR = 2.88; 95% CI = 1.31-6.29) and having 1 or more comorbid condition and 2 or more average annual visits. For the rest of the age groups, mortality in the SE only was higher than that in the PES or the epilepsy only groups. Interestingly, the hazard in the SE only group decreased from 4.84 (95% CI = 1.10-21.25) in the 1-5 year age group to 1.58 (95% CI = 1.32-1.89) in the 65 and over age group. A similar decrease was seen in the PES group compared with epilepsy only.
Limitations
There are multiple limitations associated with the nature of our database and utilization of billing and coding data. There is the potential for selection bias due to exclusion of Veterans Affairs (VA) and military hospitals from the eligible population. However, veterans and military personnel are special populations unaccounted for in nearly all population-based studies in the Unites States. There is also a possibility of misclassification error in administrative data due to coding irregularities. Further, some clinical variables of possible importance are not available in these administrative data. Such clinical variables include data on duration of SE, time to treatment initiation, SE treatment protocols, anti-seizure medications, and other intensive care interventions such as presence of mechanical ventilation, among others.
According to the recently revised International League Against Epilepsy (ILAE) definition of epilepsy, seizure recurrence may occur within the subsequent 10 years [33] . In these data, median time after diagnosis with SE or epilepsy was 4.6 years. Our study involved the use of existing data since 2000 and although lifetime history of seizures was unknown we incorporated a lag time of 2 years prior to development of SE or epilepsy to forestall misclassification. The prevalence of etiologic indicators and related mortality was also compared among the three groups and differences observed for three etiologies (brain tumor, CNS infection, and stroke). As described earlier, our study involved two case groups and one control group. SE only cases included individuals with SE without prior or subsequent epilepsy. PES cases included those with epilepsy with later diagnosis of SE. The controls were those with a diagnosis of epilepsy without SE diagnosis during the study period (i.e. prior to or following epilepsy diagnosis). Thus, the groups are mutually exclusive and the comparisons reasonable based on the developed case definitions and given the limitations of the existing data.
As the available data includes primarily hospitalization and ED visits, individuals without hospital encounters for epilepsy are not available in our database, potentially biasing these data towards more severe epilepsy. Furthermore, it is possible that some patients in the SE only group may have had prior outpatient diagnoses of epilepsy not available in our database, resulting in misclassification error. In addition, although the analysis was limited to those with at least 90 days of follow-up time, individuals with more recent SE may not have had time to receive a diagnosis of epilepsy. Individuals with multiple diagnoses of seizure NOS were counted as epilepsy only controls, potentially allowing nonepileptic patients in this group. Given that non-epileptic etiologies of seizure NOS should be associated with lower mortality than epilepsy, this may dilute our mortality rate for the epilepsy only and PES groups resulting in overestimation of the relative mortality risk for persons with SE only.
Conclusion
Findings from our population-based study comparing risk of mortality among persons with SE vs. epilepsy include heightened mortality for persons with SE only and persons with PES. Those with prior stroke, brain tumor, and CNS infection, possible etiologies for SE, had increased risk of mortality. Seizures are frightening and families worry a person may die when they experience an episode of SE. Despite its limitations, this study demonstrates increased mortality in persons who survive acute SE as well as those with PES, compared to those with epilepsy only. Important areas for future research are the relationship between long term mortality risk and specific clinical features of SE, such as etiology, severity, and treatments, and type of epilepsy-related comorbidities (e.g. somatic or psychiatric).
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